| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medical Specialties, The University of Texas Health Center at Tyler, Tyler, Texas 75708
Plasminogen activator inhibitor-1 (PAI-1), the major circulating inhibitor of urokinase [urokinase-type plasminogen activator (uPA)], has been linked to the pathogenesis of lung cancer. PAI-1 belongs to the serpin family of inhibitors and inhibits both free urokinase (uPA) and receptor-bound urokinase (uPA receptor). Although PAI-1 has been related to a poor prognosis in lung carcinoma, mechanisms that regulate its expression in human lung cancer cells are not well understood. We used cultured human small cell and non-small cell lung carcinoma cell lines as model systems to elucidate the regulatory mechanisms that control expression of PAI-1. Levels of PAI-1 protein were significantly increased in selected lung carcinoma cells compared with those in normal small-airway epithelial cells. Corresponding steady-state levels of PAI-1 mRNA were similarly increased in these cells. The half-life of PAI-1 mRNA was prolonged in these lung carcinoma cell lines after transcriptional or translational blockade. We identified a 60-kDa protein that binds the 3'-untranslated region of PAI-1, and complex formation of this binding protein with PAI-1 mRNA reciprocally correlates with mRNA stability. The findings demonstrate that expression of PAI-1 is regulated at the posttranscriptional level in small cell- and non-small cell-derived human lung carcinoma cell lines. Altered regulation of PAI-1 at the posttranscriptional level may contribute to relative overexpression by malignant lung epithelial cells. A newly identified regulatory protein that binds to the 3'-untranslated region of PAI-1 mRNA appears to be involved in the posttranscriptional regulation of PAI-1 gene expression by human lung carcinoma cells in vitro.
messenger ribonucleic acid
This article has been cited by other articles:
|
|
 |
|
  S. Shetty, J. Padijnayayveetil, T. Tucker, D. Stankowska, and S. Idell The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability Am J Physiol Lung Cell Mol Physiol, December 1, 2008; 295(6): L967 - L975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kunichika, J. W. Landsberg, Y. Yu, H. Kunichika, P. A. Thistlethwaite, L. J. Rubin, and J. X.-J. Yuan Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shetty, H. Muniyappa, P. K. S. Halady, and S. Idell Regulation of Urokinase Receptor Expression by Phosphoglycerate Kinase Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shetty and S. Idell Urokinase Receptor mRNA Stability Involves Tyrosine Phosphorylation in Lung Epithelial Cells Am. J. Respir. Cell Mol. Biol., January 1, 2004; 30(1): 69 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sweeney, Y. Yu, O. Platoshyn, S. Zhang, S. S. McDaniel, and J. X.-J. Yuan Inhibition of endogenous TRP1 decreases capacitative Ca2+ entry and attenuates pulmonary artery smooth muscle cell proliferation Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L144 - L155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. IDELL, A. P. MAZAR, P. BITTERMAN, S. MOHLA, and A. L. HARABIN Fibrin Turnover in Lung Inflammation and Neoplasia Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 578 - 584. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
